HIGH POINT, N.C., Nov. 02, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ('T1D'), today announced the appointment of Thomas Strack, M.D.

HIGH POINT，N.C.，2023年11月2日（GLOBE NEWSWIRE）-vTv Therapeutics Inc.（纳斯达克股票代码：VTVT），一家临床阶段的生物制药公司，专注于开发cadisegliatin（TTP399）作为胰岛素辅助治疗1型糖尿病（'T1D'），今天宣布任命Thomas Strack，M.D。

as Chief Medical Officer, effective immediately. “I am pleased to welcome Dr. Strack to the vTv team,” said Paul Sekhri, President and Chief Executive Officer of vTv Therapeutics. “He brings extensive drug development and clinical expertise, as well as a wealth of knowledge in endocrine, metabolic, and cardiovascular diseases.

作为首席医疗官，立即生效。vTv Therapeutics总裁兼首席执行官Paul Sekhri说：“我很高兴欢迎Strack博士加入vTv团队。”。“他带来了广泛的药物开发和临床专业知识，以及丰富的内分泌，代谢和心血管疾病知识。

We believe his expertise will be invaluable as we continue to advance toward the initiation of phase 3 study activities for cadisegliatin as an adjunctive therapy to insulin for the treatment of type 1 diabetes.” Dr. Strack joins vTv with more than 30 years of experience in academic clinical medicine and pharmaceutical drug development.

我们相信他的专业知识将是无价的，因为我们继续朝着开始3期研究活动的方向发展，将卡地格列汀作为胰岛素治疗1型糖尿病的辅助疗法。”Strack博士加入vTv，在学术临床医学和药物开发方面拥有30多年的经验。

Most recently, he served as Chief Medical Officer of Faeth Therapeutics Inc., a clinical stage developer of metabolic oncology therapies. Prior to Faeth, Dr. Strack was Senior Vice President in Clinical Development and Medical Affairs at Molecular Templates, Inc., a clinical stage biopharmaceutical company developing novel therapeutics for oncology.

最近，他担任代谢肿瘤疗法临床阶段开发者Faeth Therapeutics Inc.的首席医疗官。在Faeth之前，Strack博士是Molecular Templates，Inc。临床开发和医疗事务高级副总裁，Molecular Templates，Inc。是一家开发肿瘤新疗法的临床阶段生物制药公司。

He also served as Consultant in Medical Affairs at Omeros Corporation, a clinical stage biopharmaceutical company focused on small-molecule and protein therapeutics for immunologic disorders. Before Omeros, Dr. Strack served in senior clinical and research and development roles at Progenics Pharmaceuticals, Asubio Pharmaceuticals Inc., a subsidiary of Daiichi-Sankyo, and Pfizer.

他还曾担任Omeros Corporation医疗事务顾问，Omeros Corporation是一家专注于免疫疾病小分子和蛋白质治疗的临床阶段生物制药公司。在Omeros之前，Strack博士曾在Progenics Pharmaceuticals，第一三共子公司Asubio Pharmaceuticals Inc.和辉瑞公司担任高级临床和研究开发职位。

Previously, Dr. Strack began his industry career at Eli Lilly & Company, .

此前，Strack博士在礼来公司开始了他的职业生涯。